Literature DB >> 22093959

Bone and mineral metabolism and fibroblast growth factor 23 levels after kidney donation.

Ann Young1, Anthony B Hodsman, Neil Boudville, Colin Geddes, John Gill, David Goltzman, Sarbjit Vanita Jassal, Scott Klarenbach, Gregory Knoll, Norman Muirhead, G V Ramesh Prasad, Darin Treleaven, Amit X Garg.   

Abstract

BACKGROUND: Living kidney donation offers a unique setting to study changes in phosphate and vitamin D homeostasis attributable to mild isolated decreases in estimated glomerular filtration rate (eGFR). STUDY
DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: 198 living kidney donors and 98 nondonor controls from 9 transplant centers across 3 countries. For donors, median time after donation was 5.3 years. At assessment, donors had a lower eGFR than controls (73 vs 98 mL/min/1.73 m(2)). PREDICTOR: Living kidney donation (mildly decreased eGFR). OUTCOMES: Biochemical markers of chronic kidney disease-mineral and bone disorder. MEASUREMENTS: Serum creatinine, total serum calcium, serum and urine inorganic phosphate, plasma intact parathyroid hormone, serum calcidiol and calcitriol, renal fractional excretion of inorganic phosphate, and intact serum fibroblast growth factor 23 (FGF-23).
RESULTS: Serum FGF-23 levels were significantly higher in donors (38.1 vs 29.7 pg/mL; P < 0.001). For every 10-mL/min/1.73 m(2) decrease in eGFR, FGF-23 level was higher by 3.2 (95% CI, 2.0-4.4) pg/mL. Compared with controls, donors showed higher renal tubular fractional excretion of inorganic phosphate (17.8% vs 12.3%; P < 0.001), lower serum phosphate (0.97 vs 1.02 mmol/L; P = 0.03), and lower serum calcitriol values (63 vs 77 pmol/L; P < 0.001). Serum calcium levels were not significantly different between the 2 groups. Plasma intact parathyroid hormone levels were significantly higher in donors (5.7 vs 5.0 pmol/L; P = 0.03), but were not correlated with FGF-23 or calcitriol levels. LIMITATIONS: Enrollment of a small proportion of past donors at participating centers; assessment of only postdonation values; unable to assess seasonal variation or other temporal patterns in biochemical markers; assessment of kidney function was based on eGFR, not measured GFR.
CONCLUSIONS: The FGF-23 pathway may be activated in living kidney donors who show early biochemical changes compatible with chronic kidney disease-mineral and bone disorder. Whether these changes influence bone mineral density and fracture rates warrants consideration.
Copyright © 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22093959     DOI: 10.1053/j.ajkd.2011.09.019

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  24 in total

Review 1.  Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism.

Authors:  Makoto Kuro-o
Journal:  Nat Rev Nephrol       Date:  2013-06-18       Impact factor: 28.314

2.  Reassessing medical risk in living kidney donors.

Authors:  Robert S Gaston; Vineeta Kumar; Arthur J Matas
Journal:  J Am Soc Nephrol       Date:  2014-09-25       Impact factor: 10.121

Review 3.  Understanding and Communicating Medical Risks for Living Kidney Donors: A Matter of Perspective.

Authors:  Krista L Lentine; Dorry L Segev
Journal:  J Am Soc Nephrol       Date:  2016-09-02       Impact factor: 10.121

Review 4.  Long-term medical risks to the living kidney donor.

Authors:  Ngan N Lam; Krista L Lentine; Andrew S Levey; Bertram L Kasiske; Amit X Garg
Journal:  Nat Rev Nephrol       Date:  2015-05-05       Impact factor: 28.314

5.  Increased serum fibroblast growth factor-23 and decreased bone turnover in patients with systemic lupus erythematosus under treatment with cyclosporine and steroid but not steroid only.

Authors:  C-C Lai; W-S Chen; D-M Chang; Y-P Tsao; T-H Wu; C-T Chou; C-Y Tsai
Journal:  Osteoporos Int       Date:  2014-10-01       Impact factor: 4.507

6.  A prospective controlled study of living kidney donors: three-year follow-up.

Authors:  Bertram L Kasiske; Teresa Anderson-Haag; Ajay K Israni; Roberto S Kalil; Paul L Kimmel; Edward S Kraus; Rajiv Kumar; Andrew A Posselt; Todd E Pesavento; Hamid Rabb; Michael W Steffes; Jon J Snyder; Matthew R Weir
Journal:  Am J Kidney Dis       Date:  2015-03-17       Impact factor: 8.860

7.  A prospective controlled study of kidney donors: baseline and 6-month follow-up.

Authors:  Bertram L Kasiske; Teresa Anderson-Haag; Hassan N Ibrahim; Todd E Pesavento; Matthew R Weir; Joseph M Nogueira; Fernando G Cosio; Edward S Kraus; Hamid H Rabb; Roberto S Kalil; Andrew A Posselt; Paul L Kimmel; Michael W Steffes
Journal:  Am J Kidney Dis       Date:  2013-03-22       Impact factor: 8.860

Review 8.  Therapy for patients with CKD and low bone mineral density.

Authors:  Susan M Ott
Journal:  Nat Rev Nephrol       Date:  2013-10-08       Impact factor: 28.314

9.  Changes in biomarkers associated with living kidney donation.

Authors:  Yonghong Huan; Shiv Kapoor; Stephanie Deloach; Elizabeth Ommen; Kevin Meyers; Raymond R Townsend
Journal:  Am J Nephrol       Date:  2013-08-27       Impact factor: 3.754

10.  The unjustified classification of kidney donors as patients with CKD: critique and recommendations.

Authors:  Arthur J Matas; Hassan N Ibrahim
Journal:  Clin J Am Soc Nephrol       Date:  2013-06-27       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.